E3 PreliminaryPreliminaryPEM unclearPeer-reviewedMachine draft
Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial.
Fagermoen, Even, Sulheim, Dag, Winger, Anette et al. · BMC research notes · 2012 · DOI
Quick Summary
This small study tested whether a blood pressure medication called clonidine could be safe and helpful for teenagers with ME/CFS. Five teenagers took a low dose of clonidine for two weeks, and researchers measured drug levels in their blood, how their hearts and blood pressure responded to position changes, and any side effects. The medication appeared safe with no serious problems, and it seemed to help improve their body's blood pressure responses.
Why It Matters
Orthostatic intolerance is a common and disabling symptom in adolescent ME/CFS patients. This pilot study suggests clonidine may safely improve cardiovascular regulation in this age group, potentially opening a new therapeutic avenue and justifying larger controlled trials to establish efficacy.
Observed Findings
- Median plasma clonidine concentration after 14 days was 0.21 μg/L (range 0.18–0.36 μg/L) at trough and 0.41 μg/L (range 0.38–0.56 μg/L) at peak.
- Supine blood pressure and heart rate decreased during clonidine treatment.
- Head-up tilt-test responses moved closer to normal range during treatment.
- No serious adverse effects were registered in the five adolescent participants.
Inferred Conclusions
- Clonidine 50 μg twice daily is safe and well-tolerated in adolescents with CFS over a 14-day treatment period.
- Clonidine may improve orthostatic cardiovascular responses, bringing them closer to normal patterns.
- Safety and tolerability findings support progression to a larger controlled trial in adolescent CFS populations.
Remaining Questions
- Does clonidine improve patient-reported symptoms, fatigue severity, or functional capacity in adolescents with CFS?
- How do long-term safety and efficacy compare between clonidine and placebo or standard care in a randomized controlled trial?
- Which subgroups of CFS patients (e.g., those with documented orthostatic intolerance) are most likely to benefit from clonidine treatment?
What This Study Does Not Prove
This study does not prove clonidine is effective for ME/CFS symptoms or quality of life—it only demonstrates safety and pharmacokinetics in five adolescents. The open-label design without controls means observed improvements cannot be separated from placebo response, and findings may not generalize to adults or to unselected CFS populations.
Tags
Symptom:Orthostatic IntoleranceFatigue
Biomarker:Blood Biomarker
Phenotype:Pediatric
Method Flag:Weak Case DefinitionNo ControlsSmall SampleExploratory Only
Metadata
- DOI
- 10.1186/1756-0500-5-418
- PMID
- 22871021
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →